{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:00:37Z","timestamp":1757610037438,"version":"3.44.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-11460-x","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T07:39:15Z","timestamp":1756798755000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk factors and prevalence of latent tuberculosis infection in rheumatic patients: a meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Jincheng","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinjie","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binxue","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Can","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"issue":"1","key":"11460_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(22)00359-7","volume":"4","author":"S Bagcchi","year":"2023","unstructured":"Bagcchi S. WHO\u2019s global tuberculosis report 2022. Lancet Microbe. 2023;4(1): e20.","journal-title":"Lancet Microbe"},{"issue":"Suppl 2","key":"11460_CR2","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.rbr.2017.05.003","volume":"57","author":"CL Yonekura","year":"2017","unstructured":"Yonekura CL, Oliveira RDR, Titton DC, et al. Prevalence of tuberculosis among patients with rheumatoid arthritis using TNF blockers in brazil: data from the Brazilian registry of biological therapies in rheumatic diseases (Registro Brasileiro de Monitora\u00e7\u00e3o de terapias Biol\u00f3gicas - BiobadaBrasil)[J]. Rev Bras Reumatol Engl Ed. 2017;57(Suppl 2):477\u201383.","journal-title":"Rev Bras Reumatol Engl Ed"},{"issue":"13","key":"11460_CR3","first-page":"e33","volume":"386","author":"EB Hook","year":"2022","unstructured":"Hook EB. Latent tuberculosis infection. N Engl J Med. 2022;386(13):e33.","journal-title":"N Engl J Med"},{"key":"11460_CR4","doi-asserted-by":"crossref","unstructured":"Anton C, Machado FD, Ahumada Ramirez JM et al. Latent tuberculosis infection in patients with rheumatic diseases[J]. Jornal Brasileiro De Pneumologia. 2019;45(2):e20190023.","DOI":"10.1590\/1806-3713\/e20190023"},{"issue":"09","key":"11460_CR5","first-page":"869","volume":"44","author":"GF Deng","year":"2022","unstructured":"Deng GF, Wang QW, Chen QQ. Expert consensus on the diagnosis and treatment of latent infection of Mycobacterium tuberculosis in patients with rheumatic diseases. Chin J Anti-Tuberculosis. 2022;44(09):869\u201379.","journal-title":"Chin J Anti-Tuberculosis"},{"issue":"4","key":"11460_CR6","doi-asserted-by":"publisher","first-page":"644","DOI":"10.3855\/jidc.15839","volume":"16","author":"A Chang","year":"2022","unstructured":"Chang A, Wu C, Lin J, et al. Prevalence and risk factors for latent tuberculosis among diabetes patients in taiwan: A cross-sectional study[J]. J Infect Developing Ctries. 2022;16(4):644\u20139.","journal-title":"J Infect Developing Ctries"},{"issue":"09","key":"11460_CR7","first-page":"960","volume":"44","author":"QQ Chen","year":"2022","unstructured":"Chen QQ, Han TT, Wang QW. et, al progress in the diagnosis and treatment of rheumatic diseases with latent infection of Mycobacterium tuberculosis[J]. Chin J Anti Tuberculosis. 2022;44(09):960\u20135.","journal-title":"Chin J Anti Tuberculosis"},{"issue":"5","key":"11460_CR8","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41423-018-0004-4","volume":"15","author":"HM Knochelmann","year":"2018","unstructured":"Knochelmann HM, Dwyer CJ, Bailey SR, et al. When worlds collide: Th17 and Treg cells in cancer and autoimmunity. Cell Mol Immunol. 2018;15(5):458\u201369.","journal-title":"Cell Mol Immunol"},{"key":"11460_CR9","doi-asserted-by":"publisher","first-page":"2054431","DOI":"10.1155\/2022\/2054431","volume":"2022","author":"P Behzadi","year":"2022","unstructured":"Behzadi P, Sameer AS, Nissar S, et al. The Interleukin-1 (IL-1) superfamily cytokines and their single nucleotide polymorphisms (SNPs)[J]. J Immunol Res. 2022;2022:2054431.","journal-title":"J Immunol Res"},{"issue":"10391","key":"11460_CR10","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/S0140-6736(23)00457-9","volume":"401","author":"N Conrad","year":"2023","unstructured":"Conrad N, Misra S, Verbakel JY, et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet. 2023;401(10391):1878\u201390.","journal-title":"Lancet"},{"issue":"3","key":"11460_CR11","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s10067-024-07279-7","volume":"44","author":"J Zhong","year":"2025","unstructured":"Zhong J, Li Y, Chen Y, et al. Systemic vasculitis with latent tuberculosis infection and associated factors: a cross-sectional multicenter study. Clin Rheumatol. 2025;44(3):1269\u201377.","journal-title":"Clin Rheumatol"},{"issue":"23","key":"11460_CR12","first-page":"3576","volume":"32","author":"ZF Ren","year":"2022","unstructured":"Ren ZF, Luo H, Yang JL. Risk factors and prediction model construction of tuberculosis infection in rheumatoid arthritis. Chin J Hosp Infect. 2022;32(23):3576\u201380.","journal-title":"Chin J Hosp Infect"},{"issue":"Supplement 2","key":"11460_CR13","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1136\/annrheumdis-2017-eular.6340","volume":"76","author":"ALB Morsch","year":"2017","unstructured":"Morsch ALB, Garziera G, Otesbelgue F, et al. Latent tuberculosis infection and tuberculosis in patients with rheumatic diseases under treatment with anti-tumor necrosis factor drugs[J]. Ann Rheum Dis. 2017;76(Supplement 2):1446.","journal-title":"Ann Rheum Dis"},{"key":"11460_CR14","volume-title":"Tuberculosis: tuberculosis preventive treatment: module 1: prevention[M]","author":"WHO consolidated guidelines on","year":"2020","unstructured":"WHO consolidated guidelines on. Tuberculosis: tuberculosis preventive treatment: module 1: prevention[M]. Geneva: World Health Organization; 2020."},{"issue":"9","key":"11460_CR15","first-page":"861","volume":"35","author":"YL Shi","year":"2022","unstructured":"Shi YL, Zhao J, Ai FL, et al. Evaluating the quality of Case-control studies involving the association between tobacco exposure and diseases in a Chinese population based on the Newcastle-Ottawa scale and Post-hoc Power[J]. Biomed Environ Sci. 2022;35(9):861\u20136.","journal-title":"Biomed Environ Sci"},{"key":"11460_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10245723","author":"O Fahmy","year":"2021","unstructured":"Fahmy O, Fahmy UA, Alhakamy NA, et al. Single-port versus multiple-port robot-assisted radical prostatectomy: a systematic review and meta-analysis. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10245723.","journal-title":"J Clin Med"},{"issue":"2","key":"11460_CR17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.jaad.2021.12.012","volume":"87","author":"S Guo","year":"2022","unstructured":"Guo S, Donaldson M, Ortega-Loayza AG, et al. From the cochrane library: systemic treatments for eczema, a network meta-analysis. J Am Acad Dermatol. 2022;87(2):393\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"11460_CR18","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s10067-008-0867-3","volume":"27","author":"I Hanta","year":"2008","unstructured":"Hanta I, Ozbek S, Kuleci S, et al. The evaluation of latent tuberculosis in rheumatologic diseases for anti-TNF therapy: experience with 192 patients. Clin Rheumatol. 2008;27(9):1083\u20136.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"11460_CR19","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00296-009-1027-z","volume":"30","author":"MN Tamborenea","year":"2010","unstructured":"Tamborenea MN, Tate G, Mysler E, et al. Prevalence of positive Ppd in a cohort of rheumatoid arthritis patients. Rheumatol Int. 2010;30(5):613\u20136.","journal-title":"Rheumatol Int"},{"issue":"9","key":"11460_CR20","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1007\/s00296-011-2017-5","volume":"32","author":"CA Nobre","year":"2012","unstructured":"Nobre CA, Callado MR, Lima JR, et al. Tuberculosis infection in rheumatic patients with Infliximab therapy: experience with 157 patients. Rheumatol Int. 2012;32(9):2769\u201375.","journal-title":"Rheumatol Int"},{"issue":"7","key":"11460_CR21","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1590\/0074-02760150235","volume":"110","author":"CM Gomes","year":"2015","unstructured":"Gomes CM, Terreri MT, Moraes-Pinto MI, et al. Incidence of active mycobacterial infections in Brazilian patients with chronic inflammatory arthritis and negative evaluation for latent tuberculosis infection at baseline\u2013a longitudinal analysis after using TNFa blockers. Mem Inst Oswaldo Cruz. 2015;110(7):921\u20138.","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"8","key":"11460_CR22","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1007\/s10067-017-3714-6","volume":"36","author":"G Garziera","year":"2017","unstructured":"Garziera G, Morsch A, Otesbelgue F, et al. Latent tuberculosis infection and tuberculosis in patients with rheumatic diseases treated with anti-tumor necrosis factor agents. Clin Rheumatol. 2017;36(8):1891\u20136.","journal-title":"Clin Rheumatol"},{"issue":"8","key":"11460_CR23","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1007\/s10067-020-04991-y","volume":"39","author":"N Goel","year":"2020","unstructured":"Goel N, Torralba K, Downey C, et al. Screening for acquired latent tuberculosis in rheumatoid arthritis patients on tumor necrosis factor inhibition therapy in Southern California. Clin Rheumatol. 2020;39(8):2291\u20137.","journal-title":"Clin Rheumatol"},{"key":"11460_CR24","unstructured":"Wang XY. Analysis of factors related to tuberculosis infection in patients with systemic lupus erythematosus [D]. Nanchang University; 2020."},{"issue":"9","key":"11460_CR25","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s00296-021-04929-w","volume":"41","author":"L Oulkadi","year":"2021","unstructured":"Oulkadi L, Rostom S, Hmamouchi I, et al. Prevalence of latent tuberculosis before biotherapy initiation in rheumatoid arthritis and spondyloarthritis: data from the Moroccan biotherapy registry. Rheumatol Int. 2021;41(9):1625\u201331.","journal-title":"Rheumatol Int"},{"issue":"1","key":"11460_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.4103\/MJBL.MJBL_78_20","volume":"18","author":"SS Yousif","year":"2021","unstructured":"Yousif SS, Rasool MT. Screening for latent tuberculosis infection at a rheumatology and medical rehabilitation center in Duhok city, Iraq. Med J Babylon. 2021;18(1):23\u20137. https:\/\/doi.org\/10.4103\/MJBL.MJBL_78_20.","journal-title":"Med J Babylon"},{"issue":"4","key":"11460_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13913","volume":"53","author":"M Fornaro","year":"2023","unstructured":"Fornaro M, Stano S, Goletti D, et al. Prevalence and management of tuberculosis infection in Apulian rheumatologic patients treated with biologics: an observational cohort 10-year study from the BIOPURE registry. Eur J Clin Invest. 2023;53(4): e13913.","journal-title":"Eur J Clin Invest"},{"key":"11460_CR28","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.rcreu.2020.08.004","volume":"28","author":"C Mora","year":"2021","unstructured":"Mora C, Goyes ARB, Pati\u00f1o J, et al. Prevalence of latent tuberculosis determined using the Purified Protein Derivative (PPD) test in adult patients with rheumatoid arthritis receiving biotechnological therapy[J]. Revista Colombiana de Reumatolog\u00eda, 2021, 28(3):178\u2013183.","journal-title":"Revista Colombiana de Reumatolog\u00eda"},{"issue":"2","key":"11460_CR29","first-page":"83","volume":"70","author":"J Malinov\u00e1","year":"2021","unstructured":"Malinov\u00e1 J, H\u00e1jkov\u00e1 M, Hatalov\u00e1 A, et al. Risk of latent tuberculosis in the cohort of patients with rheumatoid arthritis in Slovakia[J]. Epidemiol Mikrobiol Imunol. 2021;70(2):83\u201390.","journal-title":"Epidemiol Mikrobiol Imunol"},{"issue":"17","key":"11460_CR30","first-page":"2165","volume":"38","author":"Rh Deng","year":"2022","unstructured":"Deng Rh, Liu LY, Liu ML. Multivariate analysis of latent tuberculosis infection in patients with rheumatoid arthritis. J Pract Med. 2022;38(17):2165\u20139.","journal-title":"J Pract Med"},{"issue":"5","key":"11460_CR31","first-page":"e39743","volume":"15","author":"D\u00c1A Zavala","year":"2023","unstructured":"Zavala D\u00c1A, Morales-Romero J, Zenteno-Cuevas R, et al. Prevalence of latent tuberculosis infection (LTBI) in Mexican patients with rheumatoid arthritis (RA)[J]. Cureus. 2023;15(5):e39743.","journal-title":"Cureus"},{"issue":"11","key":"11460_CR32","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1136\/annrheumdis-2011-200941","volume":"71","author":"S Kleinert","year":"2012","unstructured":"Kleinert S, Tony HP, Krueger K, et al. Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-\u03b3 release assays under real-life conditions. Ann Rheum Dis. 2012;71(11):1791\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"11460_CR33","doi-asserted-by":"publisher","first-page":"e295048","DOI":"10.1371\/journal.pone.0295048","volume":"19","author":"BB Hai","year":"2024","unstructured":"Hai BB, Anh TL, Thi TP, et al. Latent and active tuberculosis development in patients with rheumatoid arthritis receiving biologic disease-modifying antirheumatic drugs: A single-center prospective study[J]. PLoS ONE. 2024;19(1):e295048.","journal-title":"PLoS ONE"},{"issue":"1","key":"11460_CR34","first-page":"29","volume":"46","author":"LF Zhang","year":"2024","unstructured":"Zhang LF, Ma YN, Zou XF. etc. A multicenter cross-sectional study on the latent infection rate and related influencing factors of Mycobacterium tuberculosis in wet immune disease patients[J]. Chin J Tuberculosis Control. 2024;46(1):29\u201339.","journal-title":"Chin J Tuberculosis Control"},{"issue":"11","key":"11460_CR35","first-page":"888","volume":"43","author":"A Kahveci","year":"2025","unstructured":"Kahveci A, Akleylek C, Batibay S. Latent tuberculosis infection in inflammatory rheumatic diseases before biological and synthetic DMARD treatment: results from three rheumatology centers in different regions of Turkiye. Thorac Res Pract. 2025;43(11):888\u201391.","journal-title":"Thorac Res Pract"},{"issue":"5","key":"11460_CR36","first-page":"526","volume":"74","author":"J Perriot","year":"2024","unstructured":"Perriot J, Peiffer G, Underner M. Smoking and tuberculosis. Rev Prat. 2024;74(5):526\u20138.","journal-title":"Rev Prat"},{"key":"11460_CR37","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2147\/JMDH.S241972","volume":"13","author":"M Erawati","year":"2020","unstructured":"Erawati M, Andriany M. The prevalence and demographic risk factors for latent tuberculosis infection (LTBI) among healthcare workers in semarang, Indonesia. J Multidiscip Healthc. 2020;13:197\u2013206.","journal-title":"J Multidiscip Healthc"},{"key":"11460_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/1546-0096-12-45","volume":"12","author":"K Yasui","year":"2014","unstructured":"Yasui K. Immunity against Mycobacterium tuberculosis and the risk of biologic anti-TNF-\u03b1 reagents. Pediatr Rheumatol Online J. 2014;12: 45.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"4","key":"11460_CR39","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jmii.2013.03.005","volume":"47","author":"X Xie","year":"2014","unstructured":"Xie X, Li F, Chen JW, et al. Risk of tuberculosis infection in anti-TNF-\u03b1 biological therapy: from bench to bedside. J Microbiol Immunol Infect. 2014;47(4):268\u201374.","journal-title":"J Microbiol Immunol Infect"},{"key":"11460_CR40","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3899\/jrheum.140103","volume":"91","author":"F Cantini","year":"2014","unstructured":"Cantini F, Niccoli L, Goletti D. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-\u03b1 (TNF-\u03b1) targeted biologics and recently licensed TNF-\u03b1 inhibitors: data from clinical trials and National registries[J]. J Rheumatol Suppl. 2014;91:56\u201364.","journal-title":"J Rheumatol Suppl"},{"issue":"10","key":"11460_CR41","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1002\/acr.23487","volume":"70","author":"MK de Vries","year":"2018","unstructured":"de Vries MK, Arkema EV, Jonsson J, et al. Tuberculosis risk in ankylosing spondylitis, other spondyloarthritis, and psoriatic arthritis in Sweden: a population-based cohort study. Arthritis Care Res (Hoboken). 2018;70(10):1563\u20137.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"11460_CR42","doi-asserted-by":"publisher","first-page":"428","DOI":"10.4161\/mabs.12304","volume":"2","author":"DJ Shealy","year":"2010","unstructured":"Shealy DJ, Cai A, Staquet K, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha[J]. MAbs. 2010;2(4):428\u201339.","journal-title":"MAbs"},{"issue":"5","key":"11460_CR43","doi-asserted-by":"publisher","first-page":"285","DOI":"10.5144\/0256-4947.2021.285","volume":"41","author":"A Al-Sohaim","year":"2021","unstructured":"Al-Sohaim A, Bawazir AS, Al-Turki T, et al. The risk of tuberculosis infection in 410 Saudi patients receiving adalimumab therapy. Ann Saudi Med. 2021;41(5):285\u201392.","journal-title":"Ann Saudi Med"},{"issue":"2","key":"11460_CR44","first-page":"158","volume":"21","author":"W Wang","year":"2021","unstructured":"Wang W, Xu T, Sun TT. et, al. Analysis of clinical characteristics and related factors of rheumatoid arthritis with active pulmonary tuberculosis[J]. Chin J Infect Chemotherapy; Chin J Infect Chemother. 2021;21(2):158\u201364.","journal-title":"Chin J Infect Chemotherapy; Chin J Infect Chemother"},{"issue":"SUPPL 1","key":"11460_CR45","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1136\/annrheumdis-2020-eular.1616","volume":"79","author":"I Aachari","year":"2020","unstructured":"Aachari I, Latifa T, Fatima Zahrae T, et al. Tuberculosis infection in Moroccan patients with rheumatic diseases under biologic therapy: A multicenter National study[J]. Ann Rheum Dis. 2020;79(SUPPL 1):1245.","journal-title":"Ann Rheum Dis"},{"key":"11460_CR46","doi-asserted-by":"publisher","first-page":"1020267","DOI":"10.3389\/fcimb.2022.1020267","volume":"12","author":"K Natarajaseenivasan","year":"2022","unstructured":"Natarajaseenivasan K, Editorial. New insights in Mycobacterium tuberculosis[J]. Front Cell Infect Microbiol. 2022;12:1020267.","journal-title":"Front Cell Infect Microbiol"},{"issue":"6","key":"11460_CR47","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1080\/1040841X.2022.2035314","volume":"48","author":"H Joshi","year":"2022","unstructured":"Joshi H, Kandari D, Maitra SS, et al. Biosensors for the detection of Mycobacterium tuberculosis: a comprehensive overview. Crit Rev Microbiol. 2022;48(6):784\u2013812.","journal-title":"Crit Rev Microbiol"},{"key":"11460_CR48","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02695-2020","author":"ED Crouser","year":"2021","unstructured":"Crouser ED, Locke LW, Julian MW, et al. Phagosome-regulated mTOR signalling during sarcoidosis granuloma biogenesis. Eur Respir J. 2021. https:\/\/doi.org\/10.1183\/13993003.02695-2020.","journal-title":"Eur Respir J"},{"issue":"8","key":"11460_CR49","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1080\/15548627.2018.1474314","volume":"14","author":"M Mauthe","year":"2018","unstructured":"Mauthe M, Orhon I, Rocchi C, et al. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy. 2018;14(8):1435\u201355.","journal-title":"Autophagy"},{"issue":"1","key":"11460_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-00942-z","volume":"20","author":"Y Maharjan","year":"2022","unstructured":"Maharjan Y, Dutta RK, Son J, et al. Intracellular cholesterol transport inhibition impairs autophagy flux by decreasing autophagosome-lysosome fusion. Cell Commun Signal. 2022;20(1): 189.","journal-title":"Cell Commun Signal"},{"issue":"11","key":"11460_CR51","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s10157-021-02093-w","volume":"25","author":"Y Ogawa","year":"2021","unstructured":"Ogawa Y, Harada M, Hashimoto K, et al. Prevalence of latent tuberculosis infection and its risk factors in Japanese hemodialysis patients. Clin Exp Nephrol. 2021;25(11):1255\u201365.","journal-title":"Clin Exp Nephrol"},{"issue":"23","key":"11460_CR52","doi-asserted-by":"publisher","first-page":"135","DOI":"10.4103\/ijmr.ijmr_382_23","volume":"157","author":"A Chauhan","year":"2023","unstructured":"Chauhan A, Parmar M, Dash GC, et al. The prevalence of tuberculosis infection in india: A systematic review and meta-analysis[J]. Indian J Med Res. 2023;157(23):135\u201351.","journal-title":"Indian J Med Res"},{"issue":"3","key":"11460_CR53","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2174\/1574886316666211109092354","volume":"17","author":"S Athimni","year":"2022","unstructured":"Athimni S, Slouma M, Dhahri R, et al. Tuberculosis infection under anti-TNF alpha treatment. Curr Drug Saf. 2022;17(3):235\u201340.","journal-title":"Curr Drug Saf"},{"issue":"1\u20132","key":"11460_CR54","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0022-1759(02)00515-X","volume":"274","author":"F Puehler","year":"2003","unstructured":"Puehler F, Gobel T, Breyer U, et al. A sensitive bioassay for chicken interleukin-18 based on the inducible release of preformed interferon-gamma[J]. J Immunol Methods. 2003;274(1\u20132):229\u201332.","journal-title":"J Immunol Methods"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11460-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11460-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11460-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:21:43Z","timestamp":1756902103000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11460-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11460"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11460-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval was needed because only data from previous published studies in which informed consent was obtained by primary investigators were retrieved and analyzed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1094"}}